Time to Next Treatment Within 24 Months ( TTNT24 ) as a Predictor of Survival in Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia: A Population‐Based Observational Study
European Journal of Haematology · 2026
DOI: 10.1111/ejh.70073 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift European Journal of Haematology, 2026. Verfasst von Lars Munksgaard und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Zealand University Hospital, Roskilde, Denmark. Hauptthemen laut MEDLINE: Waldenstrom Macroglobulinemia, Time-to-Treatment. Die Arbeit nennt 29 Literaturangaben. Gefördert von: Region Zealand, Region of Southern Denmark & Region of Zealand Common Fund, A.P. Moller Foundation.
Abstract (Originalsprache)
Introduction
Prognostic models in Waldenström's macroglobulinemia (WM) are typically static, baseline tools applied before treatment initiation and do not account for dynamic post‐treatment factors. We evaluated time to next treatment within 24 months (TTNT24), as a prognostic marker in symptomatic patients, and time to lymphoma treatment within 24 months (TTLT24) in initially observed asymptomatic patients.
Methods
In this observational cohort study, patients diagnosed with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia (LPL/WM) in Region Zealand from 2000 to 2023 were identified using Danish national registries and health records. TTNT24 was defined as initiation of second‐line treatment within 24 months of first‐line therapy. TTLT24 was defined as lymphoma‐directed treatment initiated within 24 months of diagnosis in initially asymptomatic patients.
Results
Among 526 LPL/WM patients, 218 symptomatic patients were evaluated for TTNT24 with 33 (15%) patients receiving second‐line treatment within 24 months. TTNT24‐positive patients demonstrated inferior overall and lymphoma‐related survival compared to TTNT24‐negative patients. TTNT24 remained significant in multivariate analysis. Among 310 asymptomatic patients, TTLT24 was significantly associated only with lymphoma‐related survival.
Conclusion
TTNT24 and TTLT24 may serve as dynamic prognostic markers in real‐world LPL/WM populations. Their relevance in the era of targeted therapies warrants further investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology, Zealand University Hospital, Roskilde, Denmark.
- Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
- Department of Pathology, Zealand University Hospital, Roskilde, Denmark.
ORCID-Profile: Lars Munksgaard, Lars Moeller Pedersen
Förderung
- Region Zealand
- Region of Southern Denmark & Region of Zealand Common Fund
- A.P. Moller Foundation
- Region Sjælland
- A. P. Møllerske Støttefond
Zitieren
APA
Munksgaard, L., Pedersen, L. M., Munksgaard, A. S. E., & Gjerdrum, L. M. R. (2026). Time to Next Treatment Within 24 Months ( TTNT24 ) as a Predictor of Survival in Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia: A Population‐Based Observational Study. European Journal of Haematology. https://doi.org/10.1111/ejh.70073
Vancouver
Munksgaard L, Pedersen LM, Munksgaard ASE, Gjerdrum LMR. Time to Next Treatment Within 24 Months ( TTNT24 ) as a Predictor of Survival in Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia: A Population‐Based Observational Study. European Journal of Haematology. 2026. doi:10.1111/ejh.70073
BibTeX
@article{Munksgaard2026,
author = {Munksgaard, Lars and Pedersen, Lars Moeller and Munksgaard, Amalie Sofie Eilsoe and Gjerdrum, Lise Mette Rahbek},
title = {Time to Next Treatment Within 24 Months ( TTNT24 ) as a Predictor of Survival in Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia: A Population‐Based Observational Study},
journal = {European Journal of Haematology},
year = {2026},
doi = {10.1111/ejh.70073}
}
EUVIMED